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Summary
The liver and intestine play crucial roles in maintaining bile acid homeostasis. Here, we demonstrate that fibroblast growth
factor 15 (FGF15) signals from intestine to liver to repress the gene encoding cholesterol 7α-hydroxylase (CYP7A1), which
catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway. FGF15 expression is stimulated in the
small intestine by the nuclear bile acid receptor FXR and represses Cyp7a1 in liver through a mechanism that involves
FGF receptor 4 (FGFR4) and the orphan nuclear receptor SHP. Mice lacking FGF15 have increased hepatic CYP7A1 mRNA
and protein levels and corresponding increases in CYP7A1 enzyme activity and fecal bile acid excretion. These studies
define FGF15 and FGFR4 as components of a gut-liver signaling pathway that synergizes with SHP to regulate bile acid
synthesis.Introduction
Bile acids are amphipathic cholesterol metabolites that are
synthesized in the liver, stored in the gall bladder, and released
postprandially into the small intestine, where they are crucial
for the absorption of lipophilic nutrients (Chiang, 2004; Russell,
2003). As part of their enterohepatic circulation, most bile acids
(>90%) are reabsorbed in the ileum and returned via the portal
vein to the liver. Because many bile acids are strong de-
tergents, their concentrations are tightly regulated to prevent
damage to enterohepatic tissues. Expression of the gene en-
coding cholesterol 7α-hydroxylase (CYP7A1), which catalyzes
the rate limiting step in bile acid synthesis, is repressed in a
feedback fashion by bile acids (Jelinek et al., 1990; Li et al.,
1990). Expansion of the bile acid pool by administration of bile
acids suppresses CYP7A1 expression and reduces bile acid
synthesis (Jelinek et al., 1990; Li et al., 1990). Conversely, inter-
ruption of the enterohepatic circulation by biliary drainage in-
creases CYP7A1 expression and activity (Pandak et al., 1991).
Although most studies addressing the regulation of bile acid
synthesis have focused on liver, there is evidence that the in-
testine has an important role in this process beyond simply
being the site for bile acid reabsorption. In rodents, blocking
the flow of bile acids into the intestine by bile duct ligation
increases CYP7A1 expression and activity in liver (Dueland et
al., 1991; Gustafsson, 1978). Since hepatic concentrations of
bile acids increase under these conditions, this unexpected re-
sult suggests a role for the intestine in feedback repression of
bile acid synthesis. Subsequent studies in rats subjected toCELL METABOLISM : OCTOBER 2005 · VOL. 2 · COPYRIGHT © 2005 ELbiliary diversion showed that intraduodenal administration of
taurocholic acid inhibits CYP7A1 expression whereas intrave-
nous or portal administration of taurocholic acid do not (Na-
gano et al., 2004; Pandak et al., 1991). One possible explana-
tion for these results is that the intestine secretes a factor that
is important for feedback regulation of bile acid synthesis in
liver.
The nuclear bile acid receptor, FXR (NR1H4), a member of
the steroid/thyroid hormone receptor family of ligand-activated
transcription factors, plays an important role in the regulation
of bile acid homeostasis (Kok et al., 2003; Sinal et al., 2000;
reviewed by Chiang, 2004; Russell, 2003). FXR is expressed at
high levels in liver and intestine, where it is activated by the
binding of bile acids including cholic acid and chenodeoxy-
cholic acid. FXR regulates transcription by binding as a hetero-
dimer with retinoid X receptors (RXRs) to DNA response ele-
ments in the regulatory regions of target genes. Most FXR
binding sites consist of two AGTTCA half sites organized as an
inverted repeat with a single nucleotide spacer (IR-1). In liver,
FXR plays a prominent role in the feedback regulation of bile
acid synthesis (Edwards et al., 2002). Activation of FXR in-
duces expression of the gene encoding the orphan nuclear re-
ceptor SHP (small heterodimer partner; NR0B2), which in turn
binds to the orphan nuclear receptor LRH-1 (liver receptor ho-
molog 1; NR5A2) and inhibits its activation of the CYP7A1 pro-
moter (Goodwin et al., 2000; Lu et al., 2000). The importance
of SHP in the feedback regulation of bile acid synthesis was
demonstrated in SHP−/− mice, which have increased CYP7A1
expression and activity and a corresponding increase in theSEVIER INC. DOI 10.1016/j.cmet.2005.09.001 217
A R T I C L Ebile acid pool size (Kerr et al., 2002; Wang et al., 2002), and in
SHP transgenic mice, which have reduced expression of
CYP7A1 and a smaller hepatic bile acid pool size (Boulias et
al., 2005).
A recent study showed that in primary cultures of human
hepatocytes, FXR induces expression of fibroblast growth fac-
tor (FGF) 19, a secreted protein that represses CYP7A1 through
a c-Jun N-terminal kinase (JNK)-dependent pathway (Holt et
al., 2003). FGF19 selectively binds to FGF receptor 4 (FGFR4),
a transmembrane receptor with tyrosine kinase activity (Xie et
al., 1999). Mice lacking FGFR4, have an increased bile acid
pool size, reduced JNK activity and enhanced expression of
CYP7A1 (Yu et al., 2000). Conversely, transgenic mice express-
ing a constitutively active form of FGFR4 have increased JNK
activity, decreased CYP7A1 expression, and a reduced bile
acid pool size (Yu et al., 2005). These studies implicate the
FGF19/FGFR4 pathway in the regulation of bile acid homeo-
stasis. However, it is puzzling that FGF19 mRNA is not de-
tected in human liver samples by RT-PCR assays (Nishimura
et al., 1999) whereas FGFR4 is expressed in liver (Kan et al.,
1999; Nicholes et al., 2002; Stark et al., 1991).
In this report, we have evaluated the expression and function
of FGF15, the mouse ortholog of FGF19. FGF15 is shown to
be expressed and induced by FXR in small intestine but not
liver. FGF15 represses hepatic bile acid synthesis through a
mechanism that involves both FGFR4 and the orphan receptor
SHP. These studies define FGF15 and FGFR4 as components
of a gut-liver signaling pathway that cooperates with hepatic
SHP to maintain bile acid homeostasis.
Results
FGF15 is induced by FXR in intestinal epithelium
FXR was shown previously to regulate FGF19 transcription in
primary cultures of human hepatocytes by binding to an IR1
motif in the second intron of the FGF19 gene (Holt et al., 2003).
There is no FGF19 gene in the mouse genome; the most
closely related FGF family member is FGF15, which shares
51% amino acid identity (McWhirter et al., 1997). Despite their
sequence divergence, FGF15 and FGF19 appear to be or-
thologs based on synteny (Katoh, 2003; Wright et al., 2004).
Moreover, the position and sequence of the IR1 motif is con-
served in the FGF15 gene (Figure S1 in the Supplemental Data
available with this article online). Through the use of electro-
phoretic mobility shift assays and cell-based reporter assays
we showed that FXR binds to the Fgf15 IR1 motif as an RXR
heterodimer and directly regulates the Fgf15 promoter (Figure
S1). Similar results were recently reported by another group (Li
et al., 2005).
To test whether FXR stimulates FGF15 expression in vivo,
mice were treated for 14 hr with the potent, synthetic FXR ago-
nist GW4064 (Goodwin et al., 2000; Maloney et al., 2000), the
natural FXR agonist cholic acid, or vehicle. RNA was prepared
from enterohepatic tissues including liver, small intestine, and
colon. No FGF15 mRNA was detected in liver, even in mice
treated with GW4064, as assessed by northern analysis (Figure
1A) and real-time quantitative PCR (RTQ-PCR) (data not
shown). Similarly, the mRNA encoding FGF19, the human or-
tholog of FGF15, was not detected by RT-PCR in human liver
samples (Nishimura et al., 1999). FGF15 mRNA was present
in ileum, where its levels were increased by administration of218Figure 1. FGF15 expression is induced by FXR in intestinal epithelium
A) Multiple tissue Northern blot analysis was done using [32P]-labeled probes for
FGF15, SHP, FGFR4, and cyclophilin and pools of mRNA prepared from entero-
hepatic tissues of male mice (n = 5/group) treated for 14 hr with vehicle (V), cholic
acid (CA; 200 mg/kg), or GW4064 (GW; 100 mg/kg).
B) In situ hybridization was done with transverse sections of distal ileum from a
male mouse treated for 14 hr with vehicle or GW4064 using an FGF15 anti-
sense riboprobe.
C) Caco-2 cells were infected with an FGF15-expressing adenovirus and media
samples were collected at the indicated times (hr postinfection). There was no
significant cell death throughout the course of the experiments as determined by
light microscopy (data not shown). At the 72 hr time point, cell lysates were
prepared in a volume equal to that in which the cells were cultured. Equal vol-
umes of media and cell lysates were assayed for FGF15 protein by immu-
noblotting.GW4064 or cholic acid (Figure 1A). FGF15 mRNA was also de-
tected in the jejunum and duodenum of mice treated with FXR
agonists. As expected, SHP mRNA was detected in liver,
where expression was increased modestly by GW4064 (Figure
1A). SHP mRNA was also present and its expression enhanced
by FXR agonists throughout the small intestine (Figure 1A).
FGFR4 mRNA, which encodes a receptor for FGF15 (see be-
low), was most highly expressed in liver and colon, with little
or no expression detected in small intestine (Figure 1A).CELL METABOLISM : OCTOBER 2005
FGF15 regulates bile acid synthesisTo determine where FGF15 is expressed along the crypt-vil-
lus axis, in situ hybridization analysis was done using an
FGF15 antisense riboprobe and transverse sections of distal
ileum prepared from vehicle- and GW4064-treated mice. FGF15
mRNA was detected in the enterocytes of the villus epithelium
in vehicle-treated mice with highest expression in the intervillus
regions (Figure 1B). Little or no signal was detected in the
crypts or the lamina propria. GW4064 treatment increased
FGF15 mRNA hybridization and resulted in expression to the
tips of the villi (Figure 1B). No signal was detected in control
experiments performed with a sense probe (data not shown).
Like other FGFs, FGF15 has a hydrophobic N-terminal se-
quence that is presumed to be a signal sequence for secretion
(McWhirter et al., 1997). To test whether FGF15 is secreted,
Caco-2 intestinal epithelial cells, which are non-permissive for
adenovirus replication, were infected with either a recombinant
adenovirus that expresses FGF15 or a control virus, and immu-
noblotting was performed with an FGF15 antibody. FGF15 ac-
cumulated in the media of cells infected with the FGF15-
expressing adenovirus in a time-dependent manner (Figure
1C). No FGF15 was detected in experiments done with media
from control virus-infected cells at any time point (data not
shown). Comparison of FGF15 concentrations in media and
cell lysates at the 72 hr time point revealed that w50% of the
FGF15 protein was in each compartment (Figure 1C). These
data show that FGF15 is a secreted protein and suggest that
it may act in either a paracrine or endocrine fashion.
FGF15 represses Cyp7a1 in liver
Since FGF19, the human ortholog of FGF15, regulates CYP7A1,
we next examined the relationship between FGF15 and
CYP7A1 using mice in which bile flow into the small intestine
was blocked by ligation of the common bile duct. Bile duct
ligation resulted in a w3-fold increase in CYP7A1 mRNA in
liver (Figure 2A) as previously described (Dueland et al., 1991;
Gustafsson, 1978) without a corresponding decrease in SHP
expression (Figure 2B), suggesting that an activity required for
repression of Cyp7a1 is absent in the bile duct ligated mice.
Notably, FGF15 expression in ileum was extinguished in bile
duct-ligated mice (Figure 2C). Treatment of bile duct-ligated
mice with GW4064 resulted in a w50-fold increase in FGF15
mRNA in ileum, a 3.5-fold increase in SHP mRNA in liver, and
a >10-fold decrease in hepatic CYP7A1 mRNA (Figure 2). Thus,
there is an inverse relationship between FGF15 expression in
ileum and CYP7A1 expression in liver in a model of obstruc-
tive jaundice.
The reciprocal relationship between FGF15 and CYP7A1 ex-
pression raised the possibility that FGF15 regulates Cyp7a1.
To test this hypothesis directly, wild-type mice were injected
with either a recombinant adenovirus that expresses FGF15 or
a control adenovirus. In wild-type mice, infection with the
FGF15-expressing adenovirus decreased CYP7A1 mRNA levels
w5-fold (Figure 3A). Notably, SHP mRNA levels were not in-
creased by infection with the FGF15-expressing adenovirus
(Figure 3B), demonstrating that increased SHP expression is
not essential for efficient FGF15-mediated repression of Cyp7a1.
In complementary studies, purified recombinant FGF15
(Supplementary Figure 2) was injected intravenously into wild-
type mice. FGF15 resulted in a >100-fold reduction in CYP7A1
mRNA levels 6 hr after injection without causing a significant
increase in SHP mRNA levels (Figure 3D). These data demon-CELL METABOLISM : OCTOBER 2005Figure 2. Inverse relationship between FGF15 mRNA level in ileum and CYP7A1
mRNA level in liver in bile duct ligated mice
Total RNA was prepared from ileum and liver of male mice (n = 5–9) subjected to
sham operation and vehicle treatment, bile duct ligation (BDL) and vehicle treat-
ment, or bile duct ligation and GW4064 treatment. GW4064 (100 mg/kg/day) and
vehicle treatments were initiated two days prior to bile duct ligation or sham opera-
tion and continued for 4 days after surgery. Gene expression was measured by
RTQ-PCR using cyclophilin as the internal control. Data represent the mean ± SEM
and are plotted as fold change. The presence of different lowercase letters indi-
cates statistical significance (p < 0.05).strate that FGF15 can function in an endocrine fashion to sup-
press Cyp7a1.
FGFR4 and SHP contribute to FGF15-mediated
repression of Cyp7a1
Whether FGF15-mediated repression of Cyp7a1 requires
FGFR4 was investigated because (1) FGF19 binds selectively
to FGFR4 (Xie et al., 1999), (2) mice lacking FGFR4 have a bile
acid phenotype that includes elevated CYP7A1 mRNA levels
and a corresponding increase in the bile acid pool size and
fecal bile acid excretion (Yu et al., 2000); and (3) FGFR4 is the219
A R T I C L EFigure 3. FGF15-mediated repression of Cyp7a1 re-
quires FGFR4
A–C) Wild-type (WT) and FGFR4−/− mice (n =
5/group, sex matched) were infected by intravenous
injection with either a control adenovirus or an ade-
novirus that expresses FGF15. After 5 days, the
mice were killed and CYP7A1 (A), SHP (B), and
FGF15 (C) mRNA levels were measured by RTQ-
PCR using total RNA prepared from liver. Data rep-
resent the mean ± SEM and are plotted as fold
change. The presence of different lowercase letters
indicates statistical significance (p < 0.05).
D) Wild-type male mice (n = 4/group) were injected
with recombinant FGF15 (150 g/kg) or control sa-
line. Mice were killed 6 hr after injection and
CYP7A1 and SHP mRNA levels were measured by
RTQ-PCR using total RNA prepared from liver. Data
represent the mean ± SEM and are plotted as fold
change. *p < 0.001. SHP expression is not signifi-
cantly different between the two groups.predominant FGFR expressed in mature hepatocytes (Kan et
al., 1999; Nicholes et al., 2002). To determine whether FGF15
represses Cyp7a1 through FGFR4, the adenovirus experiments
described above were performed in FGFR4−/− mice. As ex-
pected, CYP7A1 mRNA levels were elevated in FGFR4−/− mice
compared to wild-type littermates (Figure 3A). In contrast to
the findings in wild-type mice, infection of FGFR4−/− mice with
the FGF15-expressing adenovirus did not repress Cyp7a1 (Fig-
ure 3A). Comparable amounts of FGF15 mRNA were present in
livers of wild-type and FGFR4−/− mice infected with the FGF15-
expressing adenovirus (Figure 3C). Thus, FGF15-mediated re-
pression of Cyp7a1 requires FGFR4.
SHP is essential for FXR-mediated repression of bile acid
synthesis (Kerr et al., 2002; Wang et al., 2002). Does repression
of Cyp7a1 by FGF15 involve SHP or do these two pathways
function independently? To address this issue, wild-type and
SHP−/− mice were treated with FGF15-expressing adenovirus
or control virus, and hepatic CYP7A1 mRNA levels were mea-
sured by RTQ-PCR. Administration of FGF15-expressing ade-
novirus to wild-type mice resulted in a >10-fold reduction in
CYP7A1 mRNA levels (Figure 4A). As expected, SHP−/− mice
had increased CYP7A1 mRNA levels (Figure 4A) as previously
reported (Kerr et al., 2002; Wang et al., 2002). However, infec-
tion of the SHP−/− mice with FGF15-expressing adenovirus re-
sulted in only a 1.4-fold repression that was not statistically
significant (Figure 4A). FGF15 mRNA levels were comparable
in wild-type and SHP−/− mice infected with FGF15-expressing
adenovirus (Figure 4B). These data reveal that SHP contributes
to FGF15-mediated repression of CYP7A1 but do not rule out
that SHP-independent mechanisms are also involved.220Bile acid homeostasis is dysregulated in FGF15−/− mice
FGF15−/− mice were recently described (Wright et al., 2004).
Most of the FGF15−/− mice die during late embryonic develop-
ment or shortly after birth, but the few FGF15−/− mice that sur-
vive appear normal. Through a large breeding program, we
were able to obtain enough FGF15−/− mice to test for alter-
ations in bile acid parameters. Notably, FGF15−/− mice had 3.5-
fold higher levels of CYP7A1 mRNA than wild-type mice (Fig-
ure 5A) with no corresponding change in SHP mRNA levels
(Figure 5B). Consistent with the mRNA data, FGF15−/− mice
had increased levels of cholesterol 7α-hydroxylase protein
(Figure 5C) and activity (Figure 5D) and a corresponding in-
crease in fecal bile acid excretion (Figure 5E). Thus, FGF15
plays a crucial role in regulating bile acid synthesis.
Is FGF15 required for FXR-mediated repression of CYP7A1
expression? To address this question, wild-type and FGF15−/−
mice were administered GW4064 or vehicle alone, and hepatic
CYP7A1 and SHP mRNA levels were analyzed by RTQ-PCR.
Administration of GW4064 to wild-type mice stimulated FGF15
expression in ileum (data not shown). Whereas GW4064 re-
pressed CYP7A1 mRNA levels by 4-fold in wild-type mice, no
repression was seen in FGF15−/− mice (Figure 5A). GW4064
administration resulted in a w2-fold induction of SHP expres-
sion in both wild-type and FGF15−/− mice, although the data in
the FGF15−/− mice did not achieve statistical significance (Fig-
ure 5B). Taken together, these data show that FGF15 is re-
quired for FXR-mediated repression of Cyp7a1.
A similar series of experiments were performed in FGFR4−/−
mice, which were administered either GW4064 or the natural
FXR agonist, cholic acid. As expected, GW4064 and cholicCELL METABOLISM : OCTOBER 2005
FGF15 regulates bile acid synthesisFigure 4. SHP contributes to FGF15-mediated repression of Cyp7a1
Wild-type (WT) and SHP−/− mice (n = 5-7/group, sex matched) fed a chow diet
containing 0.2% cholesterol were injected with either a control adenovirus or an
adenovirus that expresses FGF15. After 5 days, the mice were killed and CYP7A1
(A) and FGF15 (B) mRNA levels were measured by RTQ-PCR using total RNA
prepared from liver. Data represent the mean ± SEM and are plotted as fold
change. The presence of different lowercase letters indicates statistical signifi-
cance (p < 0.05).CELL METABOLISM : OCTOBER 2005Figure 5. Bile acid homeostasis is dysregulated in FGF15−/− mice
A) Wild-type and FGF15−/− mice (n = 10/group; male) were treated with either
vehicle or GW4064 (GW; 100 mg/kg/day) for 4 days. (A and B) CYP7A1 (A) and
SHP (B) mRNA levels were measured by RTQ-PCR using total RNA prepared
from liver. Data represent the mean ± SEM and are plotted as fold change. The
presence of different lowercase letters indicates statistical significance (p < 0.05).
C) Immunoblotting was done with liver microsomal protein prepared from wild-
type (WT) and FGF15−/− mice (n = 4; pooled samples) and antibodies against
CYP7A1 and heavy chain binding protein (BIP), which serves as a loading control.
D) Cholesterol 7α-hydroxylase activity was measured by LC/MS/MS using he-
patic microsomes isolated from wild-type (WT) and FGF15−/− mice (n = 4/group).
Data represent the mean ± SEM. *p = 0.019.
E) Fecal bile acid concentrations were measured in male wild-type (WT) and
FGF15−/− mice (n = 5/group). *p = 0.018.acid repressed Cyp7a1 in wild-type mice (Figure 6A). The effect
of both the natural and synthetic FXR agonists on CYP7A1 ex-
pression was lost in the FGFR4−/− mice (Figure 6A) even
though FGF15 mRNA was present at high levels in ileum (data
not shown). Thus, FGF15 and FGFR4 are required in addition
to SHP for FXR to repress Cyp7a1.
Discussion
Bile acids are powerful detergents whose concentrations must
be tightly regulated. Most studies of the feedback mechanisms
regulating bile acid homeostasis have focused on the liver with
little attention paid to the intestine. Nevertheless, several re-
ports reveal that the intestine is not simply a site for bile acid
reclamation but that it also plays an active and integral role in
bile acid-mediated suppression of bile acid synthesis in liver
(Nagano et al., 2004; Pandak et al., 1991). Specifically, in ro-
dents subjected to biliary diversion, intraduodenal administra-
tion of taurocholic acid inhibited CYP7A1 expression and activ-
ity whereas portal and intravenous administration of bile acids
did not. Patients with obstructive jaundice have also been re-
ported to have increased CYP7A1 mRNA and activity levels
(Bertolotti et al., 2001). These data suggest that feedback regu-lation of bile acid synthesis requires that bile acids traverse
the intestine. However, the mechanism whereby the intestine
signals to liver was unknown.
In this report, we present several lines of evidence that
FGF15 made in small intestine regulates bile acid synthesis in
liver. First, Fgf15 expression is strongly induced by the bile acid
receptor FXR in the villus epithelium of ileum (Figures 1A and
1B). This effect is mediated by an FXR response element lo-
cated in the second intron of the FGF15 gene (Figure S1). Sec-
ond, FGF15 and CYP7A1 mRNA levels are regulated in a recip-
rocal fashion in bile duct ligated mice (Figures 2A and 2C).
Third, in vivo administration of FGF15 by either infection with
an FGF15-expressing adenovirus or injection of recombinant
protein results in a marked repression of Cyp7a1 (Figures 3A
and 3D). Finally, mice lacking FGF15 have increased CYP7A1
mRNA, protein, and enzyme activity levels and a correspond-
ing increase in fecal bile acid excretion (Figure 5). These data
define a novel mechanism for the repression of bile acid syn-
thesis that involves communication between the intestine and
liver. Moreover, they reveal a new biological function for FGF15,
which was previously shown to be highly expressed in the de-
veloping central nervous system where it is postulated to regu-221
A R T I C L EFigure 6. FXR-mediated repression of Cyp7a1 requires FGFR4−/−
Wild-type (WT) and FGFR4−/− mice (n = 3–4/group, sex matched) were treated
with vehicle, cholic acid (CA; 1% administered in diet) or GW4064 (GW; 50 mg/
kg/day administered by oral gavage) for 4 days. CYP7A1 (A) and SHP (B) mRNA
levels were measured by RTQ-PCR using total RNA prepared from liver. Data
represent the mean ± SEM and are plotted as fold change. The presence of
different lowercase letters indicates statistical significance (p < 0.05). The asterisk
indicates statistical significance (p < 0.05) between the vehicle-treated wild-type
and FGFR4−/− groups.late the growth and differentiation of neural precursor cells (Gi-
meno et al., 2003, 2002; Ishibashi and McMahon, 2002).
It was previously shown that the gene encoding FGF19, the
human ortholog of mouse FGF15, is induced by FXR in primary
cultures of human hepatocytes (Holt et al., 2003). However, we
and others have not detected FGF19 mRNA in human liver
samples using sensitive RT-PCR assays (Nishimura et al.,
1999) (data not shown). These findings suggest that FGF19
may not be expressed in human liver. Although expression in
adult intestine was not tested, FGF19 is expressed in fetal in-
testine (Xie et al., 1999) and is induced in the Caco-2 intestinal
cell line by FXR agonists (Li et al., 2005), suggesting that
FGF19 may be regulated in human intestine in a manner analo-
gous to FGF15.
How does FGF15 signal between intestine and liver? One
possibility is that FGF15 affects CYP7A1 expression indirectly
by modulating the activity of bile acids or other molecules that
signal from intestine to liver. For example, FGF15 might en-
hance bile acid absorption in ileum or increase the intestinal
synthesis of a bile acid metabolite that in turn inhibits bile acid
synthesis in liver. However, it is hard to reconcile this model222with our finding that induction of FGF15 expression in ileum of
mice subjected to bile duct ligation, which blocks bile acid flow
into the small intestine, correlates with a >10-fold reduction in
CYP7A1 mRNA levels in liver (Figure 2).
A second, more intriguing possibility is that FGF15 acts as a
hormone to signal between intestine and liver (Figure 7). The
intestine produces many hormones that act in either paracrine
or endocrine fashions to influence digestion. For example, se-
cretin and cholecystokinin, which are released from enteroen-
docrine cells in the small intestine, are major regulators of exo-
crine pancreas activity. FGF15 could travel from intestine to
liver through either the portal circulation or the lymph. The lat-
ter possibility is suggested by the finding that disruption of
lymph flow increases cholesterol 7α-hydroxylase activity in rats
(Bjorkhem et al., 1978). The hypothesis that FGF15 functions
as an enterohepatic hormone is supported by data showing
that FGF15 is a secreted protein (Figure 1C) and that intrave-
nous injection of recombinant FGF15 represses CYP7A1 ex-
pression efficiently (Figure 3D). Moreover, FGFR4, which is re-
quired for FGF15-mediated repression of Cyp7a1 (Figure 3A),
is the predominant FGFR in mature hepatocytes (Kan et al.,
1999; Nicholes et al., 2002; Stark et al., 1991). To date, we
have not been able to detect FGF15 in serum, intestine, or liver
from GW4064-treated mice using several different polyclonal
antibodies. FGFs generally interact with their cognate recep-
tors with Kd values in the picomolar range (Ornitz et al., 1996),
so it is likely that our antibodies are not sufficiently sensitive to
detect biologically active concentrations of FGF15.
There is precedent for FGFs acting in an endocrine manner.Figure 7. Model for FXR-mediated repression of bile acid synthesis
Bile acids activate FXR to induce FGF15 in small intestine and SHP in liver.
FGF15 is secreted from intestine to activate FGFR4 in liver. The FGFR4 signaling
pathway cooperates with SHP to repress CYP7A1 in liver. Although SHP contrib-
utes to FGF15-mediated repression of CYP7A1, SHP-independent mechanisms
cannot be ruled out.CELL METABOLISM : OCTOBER 2005
FGF15 regulates bile acid synthesisFGF23, which is part of the same FGF subfamily as FGF15,
functions as a phosphaturic hormone (Quarles, 2003). FGF23
is expressed in liver, lymph nodes, thymus, and heart and sig-
nals to bone and kidney to regulate phosphate homeostasis.
Mutations in the FGF23 gene cause autosomal dominant hypo-
phosphatemic rickets (Consortium, 2000). There is also evi-
dence that FGF19, the human ortholog of mouse FGF15, can
act in an endocrine fashion: ectopic expression of FGF19 in
the skeletal muscle of transgenic mice enhanced proliferation
of pericentral hepatocytes and caused hepatocellular carcino-
mas (Nicholes et al., 2002; Tomlinson et al., 2002), suggesting
that FGF19 signaled from muscle to liver. Interestingly, the
crystal structure of FGF19 revealed that it contains two disul-
fide bonds, which may stabilize the protein to permit it to act
as a hormone (Harmer et al., 2004). Modeling studies predict
that FGF15 is the only other FGF family member in which both
disulfide bonds are conserved (Harmer et al., 2004). Five other
FGFs, including FGF23, are predicted to have a single disulfide
bond, which may increase their stability so that they too can
act in an endocrine fashion (Harmer et al., 2004).
Previous gene knockout studies showed that SHP is re-
quired for FXR-mediated repression of Cyp7a1 (Kerr et al.,
2002; Wang et al., 2002). In this report we demonstrate that the
FGF15/FGFR4 pathway synergizes with SHP in vivo to repress
CYP7A1 expression (Figure 7). FGF15-mediated repression of
Cyp7a1 decreases from >10-fold in wild-type mice to <1.5-fold
in SHP−/− mice (Figure 4A). These data demonstrate that SHP
contributes to FGF15-mediated repression of Cyp7a1 but do
not rule out the possibility that SHP-independent mechanisms
are also involved. Notably, administration of ectopic FGF15 re-
presses CYP7A1 expression without increasing SHP mRNA
levels (Figures 3A and 3B). Conversely, CYP7A1 mRNA levels are
increased in FGF15−/− mice without a corresponding decrease in
SHP mRNA (Figures 5A and 5B). The lack of a strict correlation
between SHP and CYP7A1 mRNA levels suggests that modu-
lation of SHP activity may be more important for CYP7A1 re-
pression than simply altering its expression levels. While the
mechanism responsible for cooperation between the FGF15/
FGFR4 and SHP pathways is not known, results from two re-
cent studies raise the possibility that they are linked by a JNK-
dependent pathway. First, FGF19 activates JNK in primary cul-
tures of human hepatocytes, and FGF19-mediated repression
of CYP7A1 is blocked by inhibitors of the JNK pathway (Holt et
al., 2003). Second, liver-specific expression of a constitutively
active FGFR4 in transgenic mice increased the amount of acti-
vated JNK in a manner that correlated with decreased expres-
sion of CYP7A1 (Yu et al., 2005).
In summary, we have demonstrated that FGF15 is selectively
induced by bile acids in small intestine and acts through
FGFR4 to repress CYP7A1 expression in liver. This work integ-
rates the FGF15/FGFR4 and SHP signaling pathways and pro-
vides a molecular explanation for the longstanding puzzle as
to why intestinal administration of bile acids represses hepatic
CYP7A1 expression and activity, whereas portal and intrave-
nous administration do not.
Experimental procedures
Animal experiments
All experiments were performed on age- and sex-matched mice. The
FGFR4−/− mice (a gift from Dr. Wallace McKeehan) are on a pure 129/Sv
background (Yu et al., 2000); both the FGF15−/− mice (a gift from Dr.CELL METABOLISM : OCTOBER 2005Thomas Reh) (Wright et al., 2004) and the SHP−/− mice (a gift from Dr. David
Russell) (Kerr et al., 2002) are on mixed C57BL/6/129/Sv backgrounds and
have been backcrossed >10 generations. Mice were housed in a temper-
ature-controlled environment with 12 hr light/dark cycles and fed standard
rodent chow ad libitum. All animal experiments were approved by the Insti-
tutional Animal Care and Research Advisory Committee at the University of
Texas Southwestern Medical Center.
Bile duct ligation
Wild-type male mice were treated daily with GW4064 (100 mg/kg/day, in
1% Tween80, 1% methylcellulose) or vehicle by gavage for 2 days prior to
surgery and 4 days after. Animals treated with GW4064 or vehicle for 2 days
were randomly assigned to one of two groups: bile duct ligation or sham
operated. The abdomen was shaved and the skin was sprayed with 70%
ethanol and wiped. Surgery was performed under aseptic conditions and
general anesthesia through an upper midline abdominal incision. The com-
mon bile duct was mobilized and ligated using 4/0 silk for the bile duct
ligated group. Sham operated mice had the same incision followed by mo-
bilization of the common bile duct without ligation. All abdominal incisions
were closed in two layers using 3/0 catgut and Micron 9 mm autoclips
(Becton Dickinson and Company, Sparks, MD).
FGF15 adenovirus and in vivo adenovirus infections
The FGF15 coding region was cloned into the pACCMVpLpA vector at
unique XbaI and HindIII sites. A (His)6 tag was included at the C terminus
to facilitate purification. Virus was prepared by cre/loxP-mediated recombi-
nation with a dl309 adenoviral cosmid in 911 cells as described previously
(Aoki et al., 1999). Viruses were propagated on 911 cells and purified using
discontinuous CsCl gradients and gel filtration on Sepharose CL-4B col-
umns as previously described (Gerard and Meidell, 1989). Mice were in-
fected with adenovirus by injection into the jugular vein using a 3/10 cc
syringe (Becton Dickinson and Company, Franklin Lakes, NJ). Each mouse
received 7.5 × 109 particles/g body weight in 0.1 ml of saline. Mice were
killed 5 days after injection and total RNA was prepared from the liver and
ileum.
Expression of FGF15 in Caco-2 cells
Confluent Caco-2 cells were infected in D2 medium with an FGF15-
expressing adenovirus or control β-galactosidase-expressing adenovirus (6
× 108 pfu/ml). After infection, the media was replaced with DMEM and me-
dia samples were collected at various times post-infection. At the final time
point, the cells were rinsed and lysed in 2 ml of 0.2% NP40, 20 mM Tris-
HCl, (pH 8.0) and the lysates centrifuged to remove debris. Immunoblotting
was done using 30 l of medium or cell lysate and a goat polyclonal FGF15
antibody (SC-16816, Santa Cruz, CA) followed by a donkey anti-goat horse-
radish peroxidase antibody (SC-2020, Santa Cruz, CA). No FGF15 was de-
tected in medium or cell lysates from control infected cells (data not shown).
Recombinant FGF15 studies
911 cells were infected with His-tagged FGF15-expressing adenovirus (6 ×
108 pfu/ml) for 16 hr. FGF15 was purified from the media using a 1 ml nickel-
agarose column (Qiagen, Valencia, CA). The column was washed succes-
sively with 25 ml of 50 mM Tris-HCl, (pH 8.0) containing 0.25 M NaCl, 25
ml of 50 mM Tris-HCl, (pH 8.0), and 25 ml of 20 mM Tris-HCl, (pH 8.0)
containing 10 mM imidazole before FGF15 was eluted with 0.5 ml of 20
mM Tris-HCl, (pH 8.0) containing 0.5 M imidazole. The protein was dialyzed
overnight in Tris-buffered isotonic saline. The purified material was a single
band as assayed by either SDS-PAGE followed by coomassie brilliant blue
staining or immunoblotting with polyclonal FGF15 antibody (Figure S2).
Purified FGF15 was injected into the jugular vein of BL6 mice at a dose of
150 g/kg body weight. Six hours after injection, the mice were anesthe-
tized and killed and total RNA prepared from their livers.
Fecal bile acid excretion
Wild-type and FGF15−/− male mice were housed individually in plastic
cages containing wood shavings and fed ad libitum. Stools were collected
from each animal over 72 hr, dried, weighed and ground in a mechanical
blender. Aliquots of ground stool were treated with sodium borohydride and
then subjected to alkaline hydrolysis at 120° for 12 hr. Fecal bile acid
content was measured enzymatically as previously described (Turley et al.,223
A R T I C L E1997). The daily stool output (g/day/100 g body weight) and fecal bile acid
content (mol/g) were used to calculate the rate of bile acid excretion (mol/
day/100 g body weight).
RNA preparation
Mice were killed and liver samples were flash-frozen in liquid nitrogen and
stored at −80°C until RNA was prepared. Small and large intestine was
removed and flushed with ice cold phosphate-buffered saline. Small intes-
tine was divided into three equal lengths designated duodenum (proximal),
jejunum (medial), and ileum (distal). The three segments were cut open lon-
gitudinally, and the mucosa were gently scraped and flash frozen in liquid
nitrogen. Total RNA was extracted using RNA STAT-60 (Tel-Test, Inc.,
Frindswood, TX).
RTQ-PCR analysis
The following primers were designed using Primer Express Software (Ap-
plied Biosystems, Foster City, CA) based on GenBank sequence data:
CYP7A1: 5#-agcaactaaacaacctgccagtacta-3#; 5#-gtccggatattcaaggatgca-3#;
FGF15: 5#-gaggaccaaaacgaacgaaatt-3#; 5#-acgtccttgatggcaatcg-3#; SHP:
5#-cgatcctcttcaacccagatg-3#; 5#-agggctccaagacttcacaca-3#; RTQ-PCR
reactions contained 25 ng of cDNA, 150 nM of each primer and 5 l of
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) in a
total volume of 10 l. All reactions were performed in triplicate on an Ap-
plied Biosystems Prism 7900HT Sequence Detection System, and relative
mRNA levels were calculated by the comparative threshold cycle method
using cyclophilin as the internal control.
Northern blot analysis
Equal amounts of total RNA from five mice/treatment group were pooled,
and mRNA was prepared using oligo(dT)-cellulose columns (Amersham
Pharmacia Biotech Inc., Piscataway NJ). mRNA (5 g/lane) was size frac-
tionated on 1% formaldehyde agarose gels and transferred to nylon mem-
brane for hybridization with 32P-labeled cDNA probes for FGF15, SHP,
FGFR4, and cyclophilin.
In situ hybridization analysis
In situ hybridization experiments were performed with paraffin-embedded
sections of ileum using 35S-labeled FGF15 sense and antisense riboprobes
(nucleotides 421–740, Genbank accession number AF007268). Slides were
exposed at 4°C for 14 days. The sections were developed, counterstained
with hematoxylin and examined using bright and darkfield optics. In all
cases, no signal was detected in sections hybridized with the sense probe
(data not shown).
CYP7A1 immunoblotting and activity
Hepatic microsomes were prepared from wild-type and FGF15−/− mice by
differential centrifugation as previously described (Schwarz et al., 1997).
CYP7A1 immunoblotting was done with a rabbit polyclonal antibody
against amino acids 476–490 of the murine protein (a gift from Dr. David
Russell) followed by an anti-rabbit IgG-conjugated horseradish peroxidase
antibody (NEF812, Perkin Elmer, Boston MA). Cholesterol 7α-hydroxylase
activity was measured in reactions performed with hepatic microsomal
preparations as previously described (Chiang, 1991). Briefly, 7α-hydroxy-
cholesterol was synthesized from endogenous cholesterol in hepatic micro-
somes incubated in the presence of NADPH. 7α-Hydroxycholesterol was
then converted to 7α-hydroxy-4-cholesten-3-one by addition of cholesterol
oxidase. β-Sitosterol, which is converted by cholesterol oxidase to β-sitos-
tenone, was included in the reactions as an internal standard. LC/MS/MS
was used to quantitate the amount of 7α-hydroxy-4-cholesten-3-one and
β-sitostenone. All data were normalized to β-sitostenone.
Statistical analyses
All results are expressed as mean ± SEM. Statistical analyses were per-
formed using Minitab Release 14 software (Minitab Inc, State College, PA).
Multiple groups were tested by one-way ANOVA followed by Fisher’s least
significant difference test for unpaired data followed by Mann Whitney U
test where appropriate. Comparisons of two groups was performed using
a Student’s t test. A p value < 0.05 was considered to be significant.224Supplemental data
Supplemental Data include two figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/2/4/217/DC1/.
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